These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 31365342)

  • 1. Treatment of familial mediterranean fever with canakinumab in patients who are unresponsive to colchicine.
    Berdeli A; Şenol Ö; Talay G
    Eur J Rheumatol; 2019 Apr; 6(2):85-88. PubMed ID: 31365342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment.
    Karabulut Y; Gezer HH; Duruöz MT
    Rheumatol Int; 2022 Jan; 42(1):81-86. PubMed ID: 34550430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Canakinumab in Colchicine- and Anakinra-Resistant or -Intolerant Adult Familial Mediterranean Fever Patients: A Single-Center Real-Life Study.
    Babaoglu H; Varan O; Kucuk H; Atas N; Satis H; Salman R; Ozturk MA; Goker B; Tufan A; Haznedaroglu S
    J Clin Rheumatol; 2020 Jan; 26(1):7-13. PubMed ID: 30048391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canakinumab in Children with Familial Mediterranean Fever: A Single-Center, Retrospective Analysis.
    Kisla Ekinci RM; Balci S; Dogruel D; Altintas DU; Yilmaz M
    Paediatr Drugs; 2019 Oct; 21(5):389-395. PubMed ID: 31463794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents.
    Eroglu FK; Beşbaş N; Topaloglu R; Ozen S
    Rheumatol Int; 2015 Oct; 35(10):1733-7. PubMed ID: 26001859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever.
    Şahin A; Derin ME; Albayrak F; Karakaş B; Karagöz Y
    Adv Rheumatol; 2020 Jan; 60(1):12. PubMed ID: 32000860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.
    Kurt T; Aydın F; Nilüfer Tekgöz P; Sezer M; Uncu N; Çelikel Acar B
    Int J Rheum Dis; 2020 Jul; 23(7):977-981. PubMed ID: 32558310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful management of colchicine resistant familial Mediterranean fever patients with a standardized canakinumab treatment protocol: a case series and literature review.
    Eren Akarcan S; Dogantan S; Edeer Karaca N; Aksu G; Kutukculer N
    Rheumatol Int; 2020 Jan; 40(1):161-168. PubMed ID: 31273456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL1-blocking therapy in colchicine-resistant familial Mediterranean fever.
    Köhler BM; Lorenz HM; Blank N
    Eur J Rheumatol; 2018 Dec; 5(4):230-234. PubMed ID: 30501849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry.
    Sag E; Akal F; Atalay E; Akca UK; Demir S; Demirel D; Batu ED; Bilginer Y; Ozen S
    Rheumatology (Oxford); 2020 Nov; 59(11):3324-3329. PubMed ID: 32306038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of Colchicine or Canakinumab in Japanese Patients with Familial Mediterranean Fever: A Single-Center Study.
    Yoshida S; Sumichika Y; Saito K; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
    J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834916
    [No Abstract]   [Full Text] [Related]  

  • 12. Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases.
    Yücel BB; Aydog O; Nalcacioglu H; Yılmaz A
    Front Pediatr; 2021; 9():710501. PubMed ID: 34568239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of canakinumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: A single-centre observational study.
    Tomokawa T; Koga T; Endo Y; Michitsuji T; Kawakami A
    Mod Rheumatol; 2022 Jul; 32(4):797-802. PubMed ID: 34897516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total Hip Joint Replacement in a Patient with Colchicine-Resistant Familial Mediterranean Fever under Canakinumab Treatment.
    Matsumoto H; Ohashi H; Fujita Y; Yoshida S; Yokose K; Temmoku J; Matsuoka N; Shinden Y; Kusano K; Sonobe T; Nakamoto Y; Yashiro-Furuya M; Asano T; Sato S; Suzuki E; Yago T; Watanabe H; Migita K
    Tohoku J Exp Med; 2022 Feb; 256(2):169-174. PubMed ID: 35236806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-interleukin-1 treatment among patients with familial Mediterranean fever resistant to colchicine treatment. Retrospective analysis.
    Sargin G; Kose R; Senturk T
    Sao Paulo Med J; 2019 May; 137(1):39-44. PubMed ID: 31116269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canakinumab treatment in children with familial Mediterranean fever: report from a single center.
    Yazılıtaş F; Aydoğ Ö; Özlü SG; Çakıcı EK; Güngör T; Eroğlu FK; Gür G; Bülbül M
    Rheumatol Int; 2018 May; 38(5):879-885. PubMed ID: 29450637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The experience of canakinumab in renal amyloidosis secondary to Familial Mediterranean fever.
    Sozeri B; Gulez N; Ergin M; Serdaroglu E
    Mol Cell Pediatr; 2016 Dec; 3(1):33. PubMed ID: 27590627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever.
    Kucuksahin O; Yildizgoren MT; Ilgen U; Ates A; Kinikli G; Turgay M; Erten S
    Mod Rheumatol; 2017 Mar; 27(2):350-355. PubMed ID: 27328763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canakinumab for the treatment of familial Mediterranean fever.
    Ozdogan H; Ugurlu S
    Expert Rev Clin Immunol; 2017 May; 13(5):393-404. PubMed ID: 28362189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canakinumab as monotherapy for treatment of familial Mediterranean fever - first report in Central and Eastern Europe region.
    Jesenak M; Hrubiskova K; Kapustova L; Kostkova M; Banovcin P
    Bratisl Lek Listy; 2018; 119(4):198-200. PubMed ID: 29663815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.